Medicus Pharma (MDCX) News Today $2.37 -1.27 (-34.89%) As of 01:52 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock MDCX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period D. Boral Capital Reiterates "Buy" Rating for Medicus Pharma (NASDAQ:MDCX)D. Boral Capital reaffirmed a "buy" rating and issued a $27.00 price objective on shares of Medicus Pharma in a report on Thursday.May 30 at 9:00 AM | marketbeat.comMedicus Pharma unveils pricing of $7M public offeringMay 30 at 8:36 AM | proactiveinvestors.comMedicus Pharma prices $7 million share offeringMay 30 at 5:31 AM | msn.comMedicus Pharma Ltd. Announces Pricing of $7.0 Million Public Offering | MDCX Stock NewsMay 29 at 10:37 PM | gurufocus.comMedicus Pharma Ltd. Launches $7 Million Public Offering to Advance Cancer Treatment TrialsMay 29 at 9:09 PM | tipranks.comMDCX Medicus Pharma Ltd.May 29 at 7:55 AM | seekingalpha.comMedicus Pharma begins UAE cancer trial expansion – ICYMIMay 25, 2025 | proactiveinvestors.comMedicus Pharma begins UAE cancer trial expansion – ICYMIMay 25, 2025 | proactiveinvestors.comMedicus Pharma's (MDCX) Buy Rating Reaffirmed at D. Boral CapitalD. Boral Capital reiterated a "buy" rating and set a $27.00 target price on shares of Medicus Pharma in a research report on Thursday.May 24, 2025 | marketbeat.comMedicus Pharma gets UAE approval for Phase 2 study for skin cancer therapyMay 22, 2025 | proactiveinvestors.comMedicus Pharma gets UAE approval for Phase 2 study for skin cancer therapyMay 22, 2025 | proactiveinvestors.comMedicus Pharma Ltd. (NASDAQ:MDCX) Major Shareholder Velocity Fund Partners, Lp Sells 75,000 SharesMay 22, 2025 | insidertrades.comMedicus Pharma (NASDAQ:MDCX) Announces Earnings Results, Misses Estimates By $0.19 EPSMedicus Pharma (NASDAQ:MDCX - Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.42) earnings per share for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.19).May 14, 2025 | marketbeat.comD. Boral Capital Boosts Medicus Pharma (NASDAQ:MDCX) Price Target to $27.00D. Boral Capital upped their price objective on shares of Medicus Pharma from $14.00 to $27.00 and gave the stock a "buy" rating in a report on Monday.May 14, 2025 | marketbeat.comMedicus Pharma LtdMay 14, 2025 | cnn.comMedicus Pharma's 'Savvy' Antev Deal De-Risks Pipeline Expansion, Enhances Near-Commercial PortfolioMay 12, 2025 | benzinga.comMedicus Pharma to acquire Antev in strategic biotech dealApril 30, 2025 | uk.investing.comMedicus Pharma (NASDAQ:MDCX) Earns "Buy" Rating from D. Boral CapitalD. Boral Capital restated a "buy" rating and issued a $14.00 target price on shares of Medicus Pharma in a report on Monday.April 30, 2025 | marketbeat.comMedicus Pharma signs letter of intent to buy British biotech companyApril 29, 2025 | bizjournals.comMedicus Pharma Ltd (MDCX)April 29, 2025 | investing.comMedicus Pharma Ltd. Announces a Binding Letter of Intent to Acquire Antev Ltd. for ~US$75 Million in a Share Exchange TransactionApril 28, 2025 | finance.yahoo.comMedicus Pharma to acquire Antev, expanding pipeline with potentially first-in-class prostate treatmentApril 28, 2025 | proactiveinvestors.comMedicus Pharma to Acquire Antev Ltd. in $75 Million DealApril 28, 2025 | tipranks.comMedicus Pharma (NASDAQ:MDCX) Receives "Buy" Rating from D. Boral CapitalD. Boral Capital reissued a "buy" rating and set a $14.00 price objective on shares of Medicus Pharma in a report on Monday.April 23, 2025 | marketbeat.comMedicus Pharma Expands Phase 2 Study for Basal Cell Carcinoma TreatmentApril 21, 2025 | tipranks.comMedicus Pharma expands basal cell carcinoma study after encouraging early dataApril 21, 2025 | proactiveinvestors.comD. Boral Capital Initiates Coverage of Medicus Pharma (MDCX) with Buy RecommendationApril 14, 2025 | msn.comResearch Analysts Set Expectations for Medicus Pharma Q1 EarningsMedicus Pharma Ltd. (NASDAQ:MDCX - Free Report) - Analysts at Brookline Capital Management issued their Q1 2025 earnings per share estimates for Medicus Pharma in a research report issued to clients and investors on Tuesday, April 8th. Brookline Capital Management analyst K. Raja forecasts that tApril 12, 2025 | marketbeat.comMedicus Pharma Ltd. (MDCX)March 25, 2025 | finance.yahoo.comMedicus Pharma announces annual meeting dateMarch 22, 2025 | investing.comMedicus Pharma Secures $4.2 Million for Innovative Skin Treatment TrialsMarch 10, 2025 | tipranks.comMedicus Pharma CEO discusses latest skin cancer trial results - ICYMIMarch 8, 2025 | proactiveinvestors.comMedicus Pharma unveils pricing of financing to advance skin cancer treatmentMarch 7, 2025 | proactiveinvestors.comMedicus Pharma announces positively trending interim analysis for SKNJCT-003March 6, 2025 | markets.businessinsider.comMedicus Pharma reports over 60% complete clearance in Phase 2 BCC trial interim resultsMarch 6, 2025 | proactiveinvestors.comMedicus Pharma Ltd Announces Positively Trending Interim Analysis for SKNJCT-003 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)March 6, 2025 | globenewswire.comMedicus Pharma Submits Phase 2 Clinical Trial Design For Non-Invasive BCC Treatment To UAEMarch 1, 2025 | nasdaq.comMedicus Pharma submits Phase 2 carcinoma clinical design in UAEFebruary 27, 2025 | markets.businessinsider.comMedicus Pharma submits Phase 2 skin cancer trial design to UAE Department of HealthFebruary 27, 2025 | proactiveinvestors.comMedicus Pharma Ltd Announces Submission of Phase 2 Clinical Design (SKNJCT-004) to United Arab Emirates (UAE) Department of Health (DOH) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)February 27, 2025 | globenewswire.comMedicus Pharma's Phase 2 skin cancer trial hits key milestone - ICYMIFebruary 22, 2025 | proactiveinvestors.comPromising Phase 2 Study and Innovative Approach Boost Confidence in Medicus Pharma Ltd.February 15, 2025 | tipranks.comMedicus Pharma Ltd: Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)February 15, 2025 | finanznachrichten.deMedicus Pharma announces phase 2 study SKNJCT-003 underwayFebruary 14, 2025 | markets.businessinsider.comMedicus Pharma expects interim data from Phase 2 skin cancer trial by quarter-endFebruary 14, 2025 | proactiveinvestors.comMedicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)February 14, 2025 | globenewswire.comMedicus Pharma Ltd MDCXFebruary 12, 2025 | morningstar.comMedicus Pharma enters SEPA, intends to voluntarily delist from TSXFebruary 12, 2025 | markets.businessinsider.comMedicus Pharma secures $15 million funding optionFebruary 12, 2025 | msn.comMedicus Pharma announces equity deal, shifts focus to NasdaqFebruary 11, 2025 | proactiveinvestors.com Get Medicus Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MDCX and its competitors with MarketBeat's FREE daily newsletter. Email Address MDCX Media Mentions By Week MDCX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MDCX News Sentiment▼0.680.88▲Average Medical News Sentiment MDCX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MDCX Articles This Week▼92▲MDCX Articles Average Week Get Medicus Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MDCX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Atai Life Sciences News CEL-SCI News MBX Biosciences News Septerna News COMPASS Pathways News Oruka Therapeutics News Kamada News Prothena News Autolus Therapeutics News Tourmaline Bio News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MDCX) was last updated on 5/30/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredTrump Just Gave the Green Light to Rewrite Social Security?In a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredUrgent: Make this trade before you hit your pillow tonight… Most people waste 8 hours every night… And 227,916 hours in their lifetime… Dreaming about the life they...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medicus Pharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medicus Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MDCX Stock Free MDCX Stock Alerts